Am­i­cus touts lat­est set of gene ther­a­py da­ta; No­vo Nordisk ex­pands dis­cov­ery deal for di­a­betes

→ The ex­ecs at Am­i­cus Ther­a­peu­tics $FOLD spared no ef­fort in tout­ing an ear­ly set of da­ta for their gene ther­a­py pro­gram to treat CLN6 Bat­ten dis­ease. At the in­ter­im, the snap­shot re­sults showed lit­tle change in 8 pa­tients treat­ed up to 24 months ago. The biotech says that they would nor­mal­ly have ex­pe­ri­enced a de­cline, giv­en his­tor­i­cal re­sults for the dis­ease. The stock, though, bare­ly budged on the up­date Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER